COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Chinese researchers develop world-first human embryo model for organ growth
- Over 1,200 individuals prosecuted for drug-related money laundering offenses since 2025: SPP
- China sees 30% decline in drug-related prosecutions since 2025
- Xizang children head home after life-changing heart surgeries
- Soundbites
- Chinese legislators urged to play bigger role in legal publicity, education
